Physician profile
Jesse Scott Swift
NPI 1235491994
$3,293.23
in general payments reported to CMS, 2019-2025
25 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $110 · 2021: $63.89 · 2022: $137 · 2023: $524 · 2024: $357 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,324.22 | 2019-2025 | Clareon Panoptix Pro, Clareon, Unity |
| Apellis Pharmaceuticals, INC. | $234.14 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $219.02 | 2022-2023 | Vabysmo, Lucentis, Susvimo |
| Abbvie INC. | $214.53 | 2022-2025 | Ozurdex, Alphagan P, Lumigan |
| Allergan, INC. | $186.98 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $164.10 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $157.77 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $155.91 | 2022-2025 | Eylea Hd, Eylea |
| Shire North American Group INC | $66.99 | 2019 | |
| Amgen INC. | $63.27 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $62.61 | 2025 | Izervay |
| New World Medical,INC. | $59.06 | 2024 | Streamline, Kahook Dual Blade, Clearpath |
| Rxsight INC | $56.14 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $38.55 | 2020-2021 | |
| Harrow Eye, LLC | $37.43 | 2025 | Iheezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $33.62 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $32.57 | 2019 | |
| Ivantis, INC | $32.38 | 2021 | |
| Horizon Therapeutics Plc | $30.68 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $28.06 | 2020 | |
| Merz Pharmaceuticals, LLC | $24.60 | 2023 | Xeomin |
| Mallinckrodt Hospital Products INC. | $22.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $19.96 | 2019 | |
| Oyster Point Pharma, INC. | $14.74 | 2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Swift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.